MetaCap

Aspen Neuroscience (ASPE) vs PepGen (PEPG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aspen Neuroscience is the larger company by market cap ($361.2 million vs $356.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASPE-16.59%PEPG+60.17%
+130%+51%-28%
Oct 30, 20261 yearNov 20, 2026
ASPE-16.59%PEPG+60.17%
+90%+34%-22%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASPE versus PEPG key metrics
MetricASPEPEPG
Share price$12.42$3.78
Market cap$361.16M$356.31M
1-day change+0.24%-3.82%
YTD return—-41.94%
1-year return—-32.01%
EPS (TTM)$-4.89$-0.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-89.66M
52-week high$14.90$7.80
52-week low$11.20$1.31
Distance from 52-week high-16.64%-51.54%
Analyst consensus—strong_buy
Avg. price target upside—+263.76%
Average volume352.42K3.26M
Shares outstanding29.08M94.26M
Employees12053
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aspen Neuroscience

ASPE stock →

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About PepGen

PEPG stock →

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees

ASPE vs PEPG FAQ

Which is bigger, Aspen Neuroscience or PepGen?

Aspen Neuroscience (ASPE) is larger, with a market capitalization of $361.16M compared with $356.31M for PepGen (PEPG).

Are Aspen Neuroscience and PepGen in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons